VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF DISITAMAB VEDOTIN FOR INJECTION FOR THE TREATMENT OF HER2-POSITIVE ADVANCED BREAST CANCER PATIENTS WITH LIVER METASTASES MET PRIMARY STUDY ENDPOINT

13 2024.06

Announcements and Notices